SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

13 May 2026 Evaluate
The total revenue for the March 2026 quarter zoomed 136.40% to Rs. 7762.50 millions as compared to Rs. 3283.60 millions during the year-ago period.The Net Profit of the company reported a remarkable increase of 666.29% to Rs. 2125.23  millions  from Rs. 277.34 millions in previous same quarter.OP of the company witnessed a marginal growth to 3193.60 millions from 582.18 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 7762.50 3283.60 136.40 20229.85 14768.37 36.98 20229.85 14768.37 36.98
Other Income 124.57 74.64 66.89 301.64 205.09 47.08 301.64 205.09 47.08
PBIDT 3193.60 582.18 448.56 6034.09 3428.08 76.02 6034.09 3428.08 76.02
Interest 72.31 23.46 208.23 239.45 82.96 188.63 239.45 82.96 188.63
PBDT 3121.29 558.72 458.65 5794.64 4109.16 41.02 5794.64 4109.16 41.02
Depreciation 250.87 168.90 48.53 917.30 655.42 39.96 917.30 655.42 39.96
PBT 2870.42 389.82 636.34 4877.34 3453.74 41.22 4877.34 3453.74 41.22
TAX 745.19 112.48 562.51 1246.29 859.48 45.01 1246.29 859.48 45.01
Deferred Tax -22.79 53.11 -142.91 -42.55 122.95 -134.61 -42.55 122.95 -134.61
PAT 2125.23 277.34 666.29 3631.05 2594.26 39.96 3631.05 2594.26 39.96
Equity 129.00 129.00 0.00 129.00 129.00 0.00 129.00 129.00 0.00
PBIDTM(%) 41.14 17.73 132.05 29.83 23.21 28.50 29.83 23.21 28.50

Neuland Laboratories Share Price

17196.15 236.20 (1.39%)
09-Jun-2026 14:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1774.20
Dr. Reddys Lab 1265.00
Cipla 1377.55
Zydus Lifesciences 1102.00
Lupin 2263.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×